drugset
drugset / Trial / NCT01126736

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

NCT01126736 ↗

Phase 1/2 Completed 98 enrolled Eisai Inc. Quintiles, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Eribulin Mesylate Administered in Combination with Pemetrexed is safe and tolerable and to gain a preliminary indication of clinical benefit when administered to Patients with Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer.

Timeline

Start
2010-06-10
Primary completion
2012-12-31
Completion
2015-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Eribulin Small molecule 0.7 mg/m2 Intravenous
Subject Eribulin Small molecule 0.9 mg/m2 Intravenous
Subject Eribulin Small molecule 1.1 mg/m2 Intravenous
Subject Eribulin Small molecule 1.4 mg/m2 Intravenous
Subject Eribulin Small molecule 2 mg/m2 Intravenous
Comparator Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma